Interaction Checker

Cookies help us deliver our services. By using our services, you agree to our use of cookies. Learn more

Interactions updated: DOACs and DAA

Friday 13 January 2023

A recent study examined the risk of clinically relevant bleeding in patients prescribed both DAAs and DOACs. They found a low incidence of bleeding which was not statistically different to historic controls of liver patients on DOACs alone. We have revised our summaries to reflect these new data. Interactions between daclatasvir, elbasvir/grazoprevir, glecaprevir/pibrentasvir, ledipasvir/sofosbuvir, sofosbuvir/velpatasvir, and sofosbuvir/velpatasvir/voxilaprevir and apixaban are now all YELLOW (potential weak interaction).

Evidence from the study has been added to the text of these interactions, and those with edoxaban and rivaroxaban where applicable. Interactions between DAAs and edoxaban and rivaroxaban remain AMBER (potential interaction). This is due to the additive effect of renal impairment with rivaroxaban, and the small numbers of patients on edoxaban included in the paper.

Safe co-administration of direct-acting antivirals and direct oral anticoagulants among patients with hepatitis C virus infection: An international multicenter retrospective cohort study. McDaniel K, Utz AE, Akbashev M et al. J Viral Hepat, 2022; doi: 10.1111/jvh.13750. Online ahead of print.

Awards and commendations
bma-foundation-for-medical-research british-medical-journal-2018 queens_aniversary_prize_2017 rcp-excellence-patient-care-awards-2017 building_better_healthcare_awards_2016